Allergy Therapeutics (LON:AGY) Shares Up 2.2% - Here's Why

Allergy Therapeutics plc (LON:AGY - Get Free Report) shares traded up 2.2% on Tuesday . The stock traded as high as GBX 6.50 ($0.08) and last traded at GBX 5.93 ($0.07). 318,980 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 551,773 shares. The stock had previously closed at GBX 5.80 ($0.07).

Allergy Therapeutics Stock Performance

The company's fifty day moving average is GBX 6.63 and its 200 day moving average is GBX 5.44. The company has a current ratio of 1.40, a quick ratio of 1.48 and a debt-to-equity ratio of 37.22. The company has a market capitalization of £302.42 million, a P/E ratio of -105.67, a P/E/G ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported GBX (1.07) (($0.01)) EPS for the quarter. Allergy Therapeutics had a negative return on equity of 155.90% and a negative net margin of 94.29%. As a group, equities analysts anticipate that Allergy Therapeutics plc will post -2.56 earnings per share for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.